美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Nasus Pharma Ltd.

2.67

+0.19007.66%

盘后：2.55-0.1200-4.49%19:40 EDT

成交量：5.04万

成交额：13.19万

市值：3,139.63万

市盈率：-10.14

高：2.69

开：2.55

低：2.51

收：2.48

52周最高：9.99

52周最低：2.40

股本：1,175.89万

流通股本：621.40万

量比：0.03

换手率：0.81%

股息：- -

股息率：- -

每股收益(TTM):-0.2633

每股收益(LYR):-0.2180

净资产收益率：--

总资产收益率：-106.39%

市净率：-7.28

市盈率(LYR):-12.25

数据加载中...

总览公司新闻资讯公告

Nasus Pharma公布Ns002二期临床研究积极顶线数据：相比Epipen®显著提升肾上腺素递送速度与疗效阈值达成效率

Nasus Pharma Ltd.盘中异动急速拉升5.41%报4.87美元

Nasus Pharma完成1500万美元私募配售定价机构投资者溢价认购

Nasus Pharma Ltd.盘中异动股价大涨10.51%

纳斯医药：完整二期试验结果预计2026年第一季度末公布；关键研究计划于2026年第四季度启动

Nasus Pharma Ltd中期结果显示Ns002较Epipen吸收更快、峰值浓度更高

Nasus Pharma Ltd.盘中异动临近午盘急速上涨5.96%

Nasus Pharma Ltd.盘中异动早盘大幅下挫8.26%

Nasus Pharma Ltd.盘中异动大幅拉升7.14%

Nasus Pharma增强领导团队，任命Eyal Rubin为执行副总裁兼首席财务官

Nasus Pharma获得加拿大卫生部批准，启动Ns002鼻用肾上腺素粉末的二期临床研究

Nasus Pharma宣布扩大协议以支持Ns002鼻内肾上腺素项目的开发和商业化

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/NSRX/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NSRX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NSRX\",,,,,undefined,":{"symbol":"NSRX","market":"US","secType":"STK","nameCN":"Nasus Pharma Ltd.","latestPrice":2.67,"timestamp":1774036800000,"preClose":2.48,"halted":0,"volume":50416,"hourTrading":{"tag":"盘后","latestPrice":2.55,"preClose":2.67,"latestTime":"19:40 EDT","volume":1489,"amount":3825.394,"timestamp":1774050028475,"change":-0.12,"changeRate":-0.044944,"amplitude":0.044944},"delay":0,"changeRate":0.07661290322580643,"floatShares":6214000,"shares":11758900,"eps":-0.263341,"marketStatus":"休市中","change":0.19,"latestTime":"03-20 16:00:00 EDT","open":2.55,"high":2.685,"low":2.51,"amount":131927.85776800002,"amplitude":0.070565,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.263341,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1774252800000},"marketStatusCode":7,"adr":0,"listingDate":1755057600000,"exchange":"AMEX","adjPreClose":2.48,"preHourTrading":{"tag":"盘前","latestPrice":2.48,"preClose":2.48,"latestTime":"09:07 EDT","volume":1917,"amount":4762.489364999999,"timestamp":1774012075516,"change":0,"changeRate":0,"amplitude":0.100806},"postHourTrading":{"tag":"盘后","latestPrice":2.55,"preClose":2.67,"latestTime":"19:40 EDT","volume":1489,"amount":3825.394,"timestamp":1774050028475,"change":-0.12,"changeRate":-0.044944,"amplitude":0.044944},"volumeRatio":0.028038263589149195},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NSRX\",,,,,undefined,":{"symbol":"NSRX","floatShares":6214000,"roa":"-106.39%","roe":"--","lyrEps":-0.217993,"volumeRatio":0.028038263589149195,"shares":11758900,"dividePrice":0,"high":2.685,"amplitude":0.070565,"preClose":2.48,"low":2.51,"week52Low":2.4,"pbRate":"-7.28","week52High":9.9899,"institutionHeld":0,"latestPrice":2.67,"eps":-0.263341,"divideRate":0,"volume":50416,"delay":0,"ttmEps":-0.263341,"open":2.55,"prevYearClose":9.15,"prevWeekClose":5,"prevMonthClose":4.79,"prevQuarterClose":9.15,"fiveDayClose":5,"twentyDayClose":5.9,"sixtyDayClose":7.0782},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NSRX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NSRX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NSRX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1766116800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NSRX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NSRX","date":"2026-03-20","current":-10.138945,"percent":1,"low":-51.389177,"twenty":-47.308794,"median":-41.395195,"eighty":-31.096524,"high":-15.239177,"avg":-39.316795,"sd":8.107946,"marketCap":29152546},"quantilePoints":[{"date":"2025-08-15","current":-47.343663,"twenty":-48.284655,"median":-47.931783,"eighty":-47.578911,"marketCap":72530491},{"date":"2025-08-22","current":-50.265593,"twenty":-50.691372,"median":-49.082873,"eighty":-48.024103,"marketCap":77006889},{"date":"2025-08-29","current":-47.604473,"twenty":-50.029049,"median":-48.047994,"eighty":-47.509856,"marketCap":72930053},{"date":"2025-09-05","current":-47.370886,"twenty":-49.082873,"median":-47.841017,"eighty":-47.486202,"marketCap":72572198},{"date":"2025-09-12","current":-48.136697,"twenty":-48.519903,"median":-47.66361,"eighty":-47.343663,"marketCap":73745420},{"date":"2025-09-19","current":-47.384488,"twenty":-48.195834,"median":-47.722745,"eighty":-47.36793,"marketCap":72593035},{"date":"2025-09-26","current":-47.604473,"twenty":-48.136697,"median":-47.604473,"eighty":-47.343663,"marketCap":72930053},{"date":"2025-10-03","current":-36.900859,"twenty":-48.077561,"median":-47.51577,"eighty":-47.308794,"marketCap":56532116},{"date":"2025-10-10","current":-45.830394,"twenty":-48.047993,"median":-47.384488,"eighty":-45.830394,"marketCap":70212163},{"date":"2025-10-17","current":-46.835706,"twenty":-47.900153,"median":-47.36793,"eighty":-45.534713,"marketCap":71752301},{"date":"2025-10-24","current":-44.943354,"twenty":-47.900153,"median":-47.314116,"eighty":-44.943354,"marketCap":68853218},{"date":"2025-10-31","current":-46.007802,"twenty":-47.900153,"median":-47.308794,"eighty":-45.239034,"marketCap":70483952},{"date":"2025-11-07","current":-44.647674,"twenty":-47.781881,"median":-47.308794,"eighty":-44.943354,"marketCap":68400236},{"date":"2025-11-14","current":-46.717433,"twenty":-47.722745,"median":-47.22009,"eighty":-44.647674,"marketCap":71571108},{"date":"2025-11-21","current":-41.395195,"twenty":-47.722745,"median":-46.835706,"eighty":-44.351994,"marketCap":63417438},{"date":"2025-11-28","current":-41.395195,"twenty":-47.675437,"median":-46.717433,"eighty":-43.654189,"marketCap":63417438},{"date":"2025-12-05","current":-40.508154,"twenty":-47.6163,"median":-46.155642,"eighty":-42.826285,"marketCap":62058492},{"date":"2025-12-12","current":-38.438395,"twenty":-47.604473,"median":-45.830394,"eighty":-41.395195,"marketCap":58887621},{"date":"2025-12-19","current":-37.669627,"twenty":-47.557164,"median":-45.682553,"eighty":-41.383368,"marketCap":57709868},{"date":"2025-12-26","current":-44.351994,"twenty":-47.509856,"median":-45.298465,"eighty":-41.395195,"marketCap":67947255},{"date":"2026-01-02","current":-43.332802,"twenty":-47.445516,"median":-44.987706,"eighty":-41.359713,"marketCap":82895651},{"date":"2026-01-09","current":-33.62436,"twenty":-47.384488,"median":-44.884218,"eighty":-40.236129,"marketCap":64323401},{"date":"2026-01-16","current":-33.62436,"twenty":-47.379047,"median":-44.647674,"eighty":-40.035066,"marketCap":64323401},{"date":"2026-01-23","current":-31.392839,"twenty":-47.370295,"median":-44.529402,"eighty":-38.570149,"marketCap":60054501},{"date":"2026-01-30","current":-26.473264,"twenty":-47.36793,"median":-44.351994,"eighty":-37.823381,"marketCap":50643354},{"date":"2026-02-06","current":-27.467787,"twenty":-47.363077,"median":-44.351994,"eighty":-35.774424,"marketCap":52545877},{"date":"2026-02-13","current":-34.411045,"twenty":-47.337754,"median":-43.81977,"eighty":-34.753161,"marketCap":65828330},{"date":"2026-02-20","current":-30.724148,"twenty":-47.314116,"median":-43.332802,"eighty":-34.411045,"marketCap":58775295},{"date":"2026-02-27","current":-31.33863,"twenty":-47.308794,"median":-42.873594,"eighty":-33.62436,"marketCap":59950800},{"date":"2026-03-06","current":-30.662699,"twenty":-47.308794,"median":-41.857638,"eighty":-33.151251,"marketCap":58657744},{"date":"2026-03-13","current":-28.389112,"twenty":-47.308794,"median":-41.483899,"eighty":-32.108896,"marketCap":54308372},{"date":"2026-03-20","current":-15.239177,"twenty":-47.308794,"median":-41.395195,"eighty":-31.096524,"marketCap":29152546}],"updateTime":1774182152557},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NSRX\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1116751624","title":"Nasus Pharma公布Ns002二期临床研究积极顶线数据：相比Epipen®显著提升肾上腺素递送速度与疗效阈值达成效率","url":"https://stock-news.laohu8.com/highlight/detail?id=1116751624","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116751624?lang=zh_cn&edition=fundamental","pubTime":"2026-03-16 19:31","pubTimestamp":1773660698,"startTime":"0","endTime":"0","summary":"Nasus Pharma Ltd.宣布其Ns002二期临床研究获得积极顶线结果。数据显示，该药物在肾上腺素递送速度方面显著优于Epipen®，能更快达到治疗阈值。\n研究证实Ns002实现了更高效的药物输送机制，为过敏急救治疗提供了新的技术突破。该进展标志着公司在该治疗领域取得重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NSRX","BK4007"],"gpt_icon":0},{"id":"2618418956","title":"Nasus Pharma Ltd.盘中异动 急速拉升5.41%报4.87美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618418956","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618418956?lang=zh_cn&edition=fundamental","pubTime":"2026-03-11 21:46","pubTimestamp":1773236767,"startTime":"0","endTime":"0","summary":"北京时间2026年03月11日21时46分，Nasus Pharma Ltd.股票出现异动，股价大幅上涨5.41%。Nasus Pharma Ltd.股票所在的制药行业中，整体跌幅为0.54%。其相关个股中，Incannex Healthcare Inc.、Shuttle Pharmaceuticals Holdings, Inc.、Nasus Pharma Ltd.涨幅较大，Hims & Hers Health, Inc.、Medicus Pharma Ltd.、Incannex Healthcare Inc.较为活跃，换手率分别为4.62%、3.78%、1.88%，振幅较大的相关个股有Incannex Healthcare Inc.、Gelteq Limited、Hims & Hers Health, Inc.，振幅分别为23.32%、13.48%、9.97%。Nasus Pharma Ltd.公司简介：Nasus Pharma Ltd是一家临床阶段的专业制药公司，主要专注于开发用于治疗紧急医疗状况的鼻内药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311214607a6b85188&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311214607a6b85188&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NSRX","BK4007"],"gpt_icon":0},{"id":"1155255765","title":"Nasus Pharma完成1500万美元私募配售定价 机构投资者溢价认购","url":"https://stock-news.laohu8.com/highlight/detail?id=1155255765","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155255765?lang=zh_cn&edition=fundamental","pubTime":"2026-02-11 12:05","pubTimestamp":1770782722,"startTime":"0","endTime":"0","summary":"以色列特拉维夫，2026年2月10日——临床阶段制药企业Nasus Pharma Ltd.今日宣布与多家机构及合格投资者签署证券购买协议，将通过私募配售发行普通股及认股权证，募集资金总额约1500万美元。根据协议条款，Nasus Pharma将合计发行2,695,425股无面值普通股，及可认购最多2,695,425股普通股的认股权证，每股普通股及配套权证的组合认购价格为5.565美元。根据协议，Nasus Pharma承诺向美国证券交易委员会提交注册声明，用于登记私募所发行普通股及权证对应普通股的转售。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4528","BK4588","UK","BK4233","NSRX","X","BK4516","BK4006","BK4205","BK4585","BK4520"],"gpt_icon":0},{"id":"2608361767","title":"Nasus Pharma Ltd.盘中异动 股价大涨10.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608361767","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608361767?lang=zh_cn&edition=fundamental","pubTime":"2026-02-04 04:19","pubTimestamp":1770149957,"startTime":"0","endTime":"0","summary":"北京时间2026年02月04日04时19分，Nasus Pharma Ltd.股票出现异动，股价快速上涨10.51%。截至发稿，该股报6.08美元/股，成交量2962股，换手率0.03%，振幅0.36%。Nasus Pharma Ltd.股票所在的制药行业中，整体跌幅为1.84%。Nasus Pharma Ltd.公司简介：Nasus Pharma Ltd是一家临床阶段的专业制药公司，主要专注于开发用于治疗紧急医疗状况的鼻内药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204041918a478b65a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260204041918a478b65a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NSRX","BK4007"],"gpt_icon":0},{"id":"1197493557","title":"纳斯医药：完整二期试验结果预计2026年第一季度末公布；关键研究计划于2026年第四季度启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1197493557","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197493557?lang=zh_cn&edition=fundamental","pubTime":"2026-01-20 21:05","pubTimestamp":1768914341,"startTime":"0","endTime":"0","summary":"纳斯医药有限公司近日披露了其研发管线的最新进展。根据公司规划，针对其主要在研产品开展的二期临床试验的完整数据，预计将在2026年第一季度末之前获得。此次数据公布将为该疗法的有效性和安全性提供更为全面的评估。\n在获得二期试验结果后，公司进一步计划于2026年第四季度正式启动关键性研究。这一阶段的研究旨在为最终向监管机构提交申请提供核心支持，是药物研发进程中至关重要的一步。上述时间表的推进，标志着纳斯医药的核心产品正向后期临床开发阶段稳步迈进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NSRX","BK4007"],"gpt_icon":0},{"id":"1141013689","title":"Nasus Pharma Ltd中期结果显示Ns002较Epipen吸收更快、峰值浓度更高","url":"https://stock-news.laohu8.com/highlight/detail?id=1141013689","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141013689?lang=zh_cn&edition=fundamental","pubTime":"2026-01-20 21:04","pubTimestamp":1768914293,"startTime":"0","endTime":"0","summary":"Nasus Pharma Ltd最新公布的中期试验数据显示，其研发的Ns002在药物吸收速度与峰值血药浓度两项关键指标上均显著优于市场主流产品Epipen。实验结果表明，Ns002能够实现更快速的系统性吸收，同时达到更高的血浆峰值水平，这一特性可能为紧急过敏反应治疗提供更高效的临床解决方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NSRX","BK4007"],"gpt_icon":0},{"id":"2601850900","title":"Nasus Pharma Ltd.盘中异动 临近午盘急速上涨5.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601850900","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601850900?lang=zh_cn&edition=fundamental","pubTime":"2026-01-06 01:00","pubTimestamp":1767632401,"startTime":"0","endTime":"0","summary":"北京时间2026年01月06日01时00分，Nasus Pharma Ltd.股票出现波动，股价快速拉升5.96%。Nasus Pharma Ltd.股票所在的制药行业中，整体跌幅为2.45%。其相关个股中，脑再生科技、Redhill Biopharma Ltd、Caring Brands, Inc.涨幅较大，Redhill Biopharma Ltd、Akanda Corp.、Cbdmd, Inc.较为活跃，换手率分别为435.01%、65.36%、11.87%，振幅较大的相关个股有脑再生科技、Scilex Holding Company C/Wts 10/11/2027 、Therapeuticsmd, Inc.，振幅分别为30.04%、27.22%、21.38%。Nasus Pharma Ltd.公司简介：Nasus Pharma Ltd是一家临床阶段的专业制药公司，主要专注于开发用于治疗紧急医疗状况的鼻内药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106010001a6f6c28a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106010001a6f6c28a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NSRX"],"gpt_icon":0},{"id":"2593460473","title":"Nasus Pharma Ltd.盘中异动 早盘大幅下挫8.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593460473","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593460473?lang=zh_cn&edition=fundamental","pubTime":"2025-12-22 22:55","pubTimestamp":1766415302,"startTime":"0","endTime":"0","summary":"北京时间2025年12月22日22时55分，Nasus Pharma Ltd.股票出现波动，股价急速跳水8.26%。截至发稿，该股报6.95美元/股，成交量561股，换手率0.01%，振幅0.00%。Nasus Pharma Ltd.股票所在的制药行业中，整体涨幅为0.29%。Nasus Pharma Ltd.公司简介：Nasus Pharma Ltd是一家临床阶段的专业制药公司，主要专注于开发用于治疗紧急医疗状况的鼻内药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222225502a46af501&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222225502a46af501&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NSRX","BK4007"],"gpt_icon":0},{"id":"2585171598","title":"Nasus Pharma Ltd.盘中异动 大幅拉升7.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585171598","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585171598?lang=zh_cn&edition=fundamental","pubTime":"2025-11-22 01:57","pubTimestamp":1763747821,"startTime":"0","endTime":"0","summary":"北京时间2025年11月22日01时57分，Nasus Pharma Ltd.股票出现异动，股价快速上涨7.14%。Nasus Pharma Ltd.股票所在的制药行业中，整体涨幅为1.56%。其相关个股中，Alvotech C/Wts 、Sunshine Biopharma Inc C/Wts 、Scilex Holding Company涨幅较大，Shuttle Pharmaceuticals Holdings, Inc.、Inmed Pharmaceuticals Inc.、Akanda Corp.较为活跃，换手率分别为230.65%、9.95%、8.03%，振幅较大的相关个股有Alvotech C/Wts 、Shuttle Pharmaceuticals Holdings, Inc.、Caring Brands, Inc.，振幅分别为38.81%、27.92%、19.67%。Nasus Pharma Ltd.公司简介：Nasus Pharma Ltd是一家临床阶段的专业制药公司，主要专注于开发用于治疗紧急医疗状况的鼻内药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251122015702a4b21ff7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251122015702a4b21ff7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NSRX","BK4007"],"gpt_icon":0},{"id":"1186579067","title":"Nasus Pharma增强领导团队，任命Eyal Rubin为执行副总裁兼首席财务官","url":"https://stock-news.laohu8.com/highlight/detail?id=1186579067","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186579067?lang=zh_cn&edition=fundamental","pubTime":"2025-11-20 21:17","pubTimestamp":1763644660,"startTime":"0","endTime":"0","summary":"Nasus Pharma增强领导团队，任命Eyal Rubin为执行副总裁兼首席财务官","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NSRX"],"gpt_icon":0},{"id":"1150703630","title":"Nasus Pharma获得加拿大卫生部批准，启动Ns002鼻用肾上腺素粉末的二期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1150703630","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150703630?lang=zh_cn&edition=fundamental","pubTime":"2025-11-06 21:03","pubTimestamp":1762434188,"startTime":"0","endTime":"0","summary":"Nasus Pharma获得加拿大卫生部的批准，计划启动Ns002鼻用肾上腺素粉末的二期临床研究。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NSRX","BK4007"],"gpt_icon":0},{"id":"1175095310","title":"Nasus Pharma宣布扩大协议以支持Ns002鼻内肾上腺素项目的开发和商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=1175095310","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175095310?lang=zh_cn&edition=fundamental","pubTime":"2025-10-08 20:06","pubTimestamp":1759925171,"startTime":"0","endTime":"0","summary":"Nasus Pharma宣布扩大协议以支持Ns002鼻内肾上腺素项目的开发和商业化","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NSRX","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":12,"code":"91000000","status":"200"}]}}